Home > Insider Trading > Filing (0001192482-19-000419)

Filing Details

Accession Number:: 0001192482-19-000419
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-11-13 20:47:53
Reporting Period:: 2019-11-08

Accepted Time:: 2019-11-13 20:47:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1561921	Tela Bio Inc.	TELA	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue, 54Th Floor New York NY 10022		No	No	Yes	No
1502240	Orbimed Capital Gp Iv Llc	601 Lexington Avenue, 54Th Floor New York NY 10022		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-11-08	384,615	$13.00	1,568,627	No	4	P	Direct
Common Stock	Acquisiton	2019-11-13	481,095	$0.00	2,049,722	No	4	C	Direct
Common Stock	Acquisiton	2019-11-13	977,820	$0.00	3,027,542	No	4	C	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	C	Direct
No	4	C	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-11-13	11,878,249	$0.00	481,095	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-11-13	24,142,419	$0.00	977,820	$0.00
Series B Preferred Stock	Warrant (right to buy)	Disposition	2019-11-13	758,623	$0.00	758,623	$1.16
Common Stock	Warrant (right to buy)	Acquisiton	2019-11-13	758,623	$0.00	30,725	$28.65

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct
0	2017-01-18	2027-01-18	No	4	C	Direct
758,623	2019-11-13	2027-01-18	No	4	C	Direct

Footnotes

Reflects 1,184,012 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors"), a registered advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IV noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee consisting of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI IV.
Each of GP IV and Advisors disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.